Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hui-Gene Therapeutics

Request full access

Focused on R&D for single-gene disorders and has developed pilot pipes in neurodegenerative diseases

Huangpu, ChinaFounded 2018Biotech & Life Sciences

About Hui-Gene Therapeutics

HuidaGene Therapeutics is a biotechnology startup that operates in the medical research and development sector. The company focuses on developing innovative treatments for a range of diseases in the fields of neurology, ophthalmology, and myology. Its research pipelines include work on conditions such as MECP2 Duplication Syndrome, Huntington's Disease, Amyotrophic Lateral Sclerosis, inherited retinal dystrophies, age-related macular degeneration, retinitis pigmentosa, and Duchenne Muscular Dystrophy.

HuidaGene's business model revolves around the research, development, and commercialization of novel therapies. The company's primary clients are patients suffering from the aforementioned diseases, with a particular focus on rare and orphan diseases. Orphan diseases are conditions that affect a small percentage of the population, and the treatments for these conditions are often referred to as 'orphan drugs'.

The company generates revenue through the development and sale of these therapies. It is also actively seeking to expand its global collaborations, as evidenced by its participation in international conferences such as the BIO-Europe Fall Conference.

Recently, HuidaGene announced the dosing of its first patient in a multinational Phase 1/2 trial for inherited blindness. Additionally, the U.S. FDA has awarded both Rare Pediatric Disease and Orphan Drug Designations to HG204, a CRISPR RNA-editing therapy developed by HuidaGene for the treatment of MECP2 Duplication Syndrome.

Source: Dealroom company data

At a glance

Status
Operational
Employees
28
Open positions
None listed
Dealroom signal
61.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing May 2022 $0 — CD Capital · Kunlun Capital · Sherpa Venture Partners ↗
SERIES BOther financing Jun 2021 $62M $248M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Hui-Gene Therapeutics website traffic

Latest recorded traffic for Hui-Gene Therapeutics is 2.8K monthly website visits, up 7.7% over the last three months. Hui-Gene Therapeutics's team declined 6.7% over the past year.

Latest monthly visits2.8K 3-month web change+7.7% 1-year team growth-6.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hui-Gene Therapeutics in the Huangpu ecosystem

Live from Dealroom

The Hui-Gene Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • CD Capital
  • WuXi AppTec

Series B and later2 investors entered at this stage

  • Kunlun Capital
  • Sherpa Venture Partners

Other known investors1 additional known investor

  • Chinese Academy Of Sciences
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇳 China90%
🇭🇰 Hong Kong5%
🇺🇸 United States5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hui-Gene Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hui-Gene Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.